Developing a peptide to disrupt cohesin head domain interactions

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Cohesin is crucial for 3-D chromatin structure, genome stability, and function.
• The cohesin core, composed of Smc1 and Smc3 proteins, utilizes an ATPase cycle essential for its activity.
• Understanding cohesin's mechanism is key to exploring its role in cellular processes and disease.

Purpose of the Study:

• To develop the first peptide inhibitor targeting cohesin.
• To investigate the mechanism of action and cellular effects of a novel cohesin-inhibiting peptide (CIP).
• To assess the potential of CIPs as a therapeutic strategy.

Main Methods:

• In vitro binding assays to confirm CIP interaction with Smc3.
• Enzyme activity assays to measure inhibition of cohesin's ATPase activity.
• Cellular studies in yeast and human cells to evaluate the effects of CIP on cohesin function and localization.

Main Results:

• The developed peptide (CIP) successfully binds Smc3 in vitro.
• CIP effectively inhibits the ATPase activity of the cohesin holocomplex.
• CIP treatment in yeast cells disrupts cohesin's tethering activity and causes cohesin accumulation on chromatin, with similar effects observed in human cells.

Conclusions:

• Peptides can be effectively utilized to inhibit cohesin function within cellular systems.
• The novel cohesin-inhibiting peptides (CIPs) demonstrate a powerful approach to modulate cohesin activity.
• CIPs hold potential as a therapeutic avenue for conditions involving cohesin dysregulation.